Lifestyle Factors Combining GLP-1 agonist therapy with lifestyle modifications is essential for maximising weight loss and improving overall health
1 Weight loss results: Tirzepatide: approximately 12% body weight loss from baseline Dulaglutide 1.5 mg: approximately 5% body weight loss from baseline Difference: roughly 7 percentage points in favour of tirzepatide Blood sugar control: Tirzepatide: -1.73% HbA1c reduction Dulaglutide 1.5 mg: -0.90% HbA1c reduction Difference: approximately 0.83 percentage points in favour of tirzepatide Cardiovascular outcomes Both medications have demonstrated cardiovascular safety and benefit in people with type 2 diabetes
As GLP-1 therapies become more widely used, its essential we pair them with clear, accessible guidance that helps patients maintain long-term health and minimize side effects
In 2025, the global pharmaceutical market landscape underwent another major reshuffle
The relevance to tirzepatide is indirect, but the low risk profile makes it a reasonable adjunct when anxiety-mediated nausea worsens vomiting
You might experience nausea, cramping, diarrhea, or digestive problems when you first start taking the weekly medication